Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients

University of Alberta

Status: Completed

Conditions: Transplant

Study type: Observational

Funder types: Other

Identifiers

NCT01149382

KUOA-03-ITP

Details and patient eligibility

About

Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown that the standard inactivated influenza vaccine has poor immunogenicity in this population. The investigators plan to test the humoral response to vaccination and look at HLA upregulation

Full description

OBJECTIVE AND HYPOTHESIS

• To test the specific humoral response of the influenza vaccine after islet cell transplantation
• To test the production of HLA alloantibodies after vaccination.

Enrollment: 61 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult islet cell transplant recipients
• Able to provide informed consent

Exclusion criteria

• Egg allergy
• Previous life-threatening reaction to influenza vaccine (ie Guillain Barre Syndrome)
• Febrile illness in the past two weeks
• Unable to provide informed consent

Trial design

61 participants in 1 patient group

islet cell transplant recipients